Risk Forecasting Dashboard

Predict probability of efficacy failure, safety signals, and enrollment delays

6

High Risk Trials

34%

Avg Efficacy Risk

12%

Avg Safety Risk

23%

Avg Enrollment Risk

Trial Risk Assessment Matrix

Phase III Oncology - Solid Tumors

NCT-2024-045
Success Probability:54%
Low Risk
Efficacy Risk22%
Safety Risk8%
Enrollment Risk15%

Phase II Cardiovascular - Heart Failure

NCT-2024-038
Success Probability:41%
High Risk
Efficacy Risk45%
Safety Risk18%
Enrollment Risk34%

Phase I Neurology - Alzheimer's

NCT-2024-052
Success Probability:32%
High Risk
Efficacy Risk58%
Safety Risk22%
Enrollment Risk12%

Phase II Immunology - Autoimmune

NCT-2024-061
Success Probability:67%
Low Risk
Efficacy Risk18%
Safety Risk6%
Enrollment Risk9%

Risk Trend Analysis

Portfolio Risk Score
-8% from last month

2.8 / 5.0

January 2026
3.4
December 2025
3.1
November 2025
2.8

Risk Mitigation Actions

Implement adaptive design for NCT-2024-038

Reduces efficacy risk by ~15%

Pending approval

High

Add interim safety monitoring for NCT-2024-052

Early detection of safety signals

In progress

High

Expand enrollment sites for NCT-2024-038

Reduces enrollment delay risk by ~20%

Planned

Medium